Huberman LabSupplements for Longevity & Their Efficacy | Dr. Peter Attia
At a glance
WHAT IT’S REALLY ABOUT
Huberman, Attia Dismantle NAD Longevity Hype, Prioritize Real Lifespan Levers
- Andrew Huberman and Peter Attia examine the scientific basis for using NAD, NR, and NMN supplements to extend lifespan or improve healthspan, and conclude that current evidence is extremely weak. They walk through the full backstory: sirtuins, caloric restriction, NAD biology, and the key mouse and human studies, showing where popular narratives diverge sharply from actual data.
- Attia emphasizes that rapamycin and caloric restriction are the only interventions with consistent, cross-species lifespan extension data, whereas NR/NMN have failed in rigorous lifespan testing (ITP) and show, at best, small, clinically trivial effects in humans. The one possible bright spot is a preliminary signal for reduced non-melanoma skin cancers.
- Both underscore that behavior—sleep, exercise, nutrition, emotional health—dwarfs any supplement or infusion (including NAD drips) in impact on longevity and vitality. They close by transparently sharing their own supplement regimens and reiterating that almost all of the NAD-related hype is unsupported by robust science.
IDEAS WORTH REMEMBERING
5 ideasThe NAD–NR–NMN longevity narrative rests on multiple unproven leaps of faith.
Attia spells out the chain of assumptions: (1) sirtuins modestly extend lifespan in yeast and one transgenic mouse model; (2) this is assumed to generalize to humans; (3) NAD decline with age is assumed to be causally important; (4) raising NAD (via NR/NMN or NAD infusions) is assumed to restore sirtuin-mediated benefits; and (5) all of this is assumed to translate into human lifespan extension. None of these links has strong experimental support in humans.
Rigorous lifespan testing in mice shows NR/NMN do not extend life, while rapamycin and glucose-control drugs do.
The NIH-funded Interventions Testing Program (ITP), run in triplicate at three independent labs in genetically heterogeneous mice, is the gold standard for lifespan interventions. NR failed to extend lifespan at high doses; rapamycin, canagliflozin (SGLT2 inhibitor), and acarbose did extend lifespan, often without changes in body weight, highlighting blood glucose regulation and mTOR modulation as genuinely promising levers.
Human NR/NMN trials show, at best, small, often clinically trivial effects.
One NR+pterostilbene trial in people with fatty liver found no overall change in liver fat, weight, glycemia, or inflammation; only a post‑hoc subset with moderate steatosis showed a modest drop in liver fat that remained well above disease thresholds. An NMN trial showed a minor increase in insulin-stimulated glucose disposal, comparable in magnitude to red-light-on-the-back before a glucose challenge. These effects are statistically significant but not meaningfully life-changing.
A single potentially meaningful NR/NMN signal is reduction in non-melanoma skin cancers, but needs replication.
Attia highlights one study suggesting a 60–80% reduction in basal cell and squamous cell carcinoma incidence with NAD-precursor supplementation, with no effect on melanoma. Because skin shows the steepest age-related NAD decline, this could be a real, tissue-specific benefit, especially for high–sun exposure or high-risk individuals—but the result is preliminary and requires confirmation before being used as a primary rationale.
Raising blood NAD does not automatically mean meaningful cellular or clinical benefit.
NR clearly raises blood (and likely liver) NAD; NMN likely does as well after dephosphorylation. But NAD is tightly regulated, and total NAD+NADH may not change materially—what declines with age may be redox potential and mitochondrial function, not simply NAD concentration. Current evidence does not show that pushing NAD above physiologic levels improves lifespan, healthspan, or performance in a substantial way.
WORDS WORTH SAVING
5 quotesEverything we have talked about on this podcast today, whether it be NR, NAD, NMN… all of that stuff… I would put in the category of: was the Titanic serving lobster or steak? Exercise, sleep, nutrition, emotional health is the question of what was the heading of the Titanic.
— Peter Attia
There are only two interventions, full stop, that have ever extended life across those four categories of eukaryotes: caloric restriction and rapamycin.
— Peter Attia
The single thing I can say with the greatest confidence is there is no evidence whatsoever that sirtuins have anything to do with caloric restriction and vice versa.
— Peter Attia
I passionately do not believe [NR/NMN] do anything for me, and why would I waste time, money, anything, on something that I really don't believe makes a difference?
— Peter Attia
If you had an extra two hours a week to choose between paying $1,000 for an NAD infusion or lift weights for an hour, go for a half-hour walk, and then eat a meal… I can just think of so many better ways to spend time and money.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome